ara-290 Peptide Therapy

ARA-290 (cibinetide) is a non-erythropoietic peptide engineered from a small region of erythropoietin (EPO). It’s being investigated for small-fiber neuropathy (SFN), tissue protection, and inflammation modulation via the innate repair receptor pathway. At The Catalyst Clinic, ARA-290 is considered only within a physician-led programme with appropriate screening and follow-up.

What is Ara-290?

ARA-290 is a short peptide—also called Helix-B Surface Peptide (HBSP)—designed to activate the innate repair receptor (IRR), a heteromer of the EPO receptor and CD131. Unlike full EPO, ARA-290 does not stimulate red-blood-cell production. In clinical studies it has typically been given as a once-daily subcutaneous injection over several weeks. (Also known as cibinetide.) PMC+2PMC+2

  • Non-erythropoietic: Tissue-protective signalling without raising haematocrit. PMC

  • Innate repair receptor activation: Downstream effects include reduced pro-inflammatory cytokines and cytoprotection.

Benefits of AOD-9604

Research and clinical interest suggest that AOD-9604 may:

  • • Promote fat loss – particularly around the abdominal region
  • • Support weight management – by balancing fat storage and fat burning
  • • Improve lipid profile – potential positive effects on cholesterol and blood lipids
  • • Avoid blood sugar disruption – no consistent negative impact on glucose or insulin sensitivity
  • • Protect cartilage – early studies suggest possible cartilage-protective and regenerative effects

How AOD-9604 Works

AOD-9604 works by mimicking the fat-regulating actions of natural HGH:

  • • Stimulates lipolysis – breaking down stored fat into fatty acids for energy
  • • Inhibits lipogenesis – reducing the body’s tendency to store new fat
  • • Enhances fatty acid oxidation – encouraging the body to use fat for fuel

Unlike HGH, AOD-9604 does not promote tissue growth, making it a potentially safer option for weight and metabolism support.

Potential Therapeutic Applications

AOD-9604 has been studied for:

  • • Weight management – supporting fat loss programmes
  • • Obesity treatment – explored in clinical trials as a therapeutic option
  • • Cartilage protection – potential role in joint health and repair (early-stage research)
  • • Metabolic support – improving lipid and energy balance

Note: AOD-9604 remains investigational outside specific approved uses and should only be used under professional supervision.

Administration

Typical method: Subcutaneous injection (under the skin)

  • • Dosage: Often reported between a few hundred micrograms to 1mg per day
  • • Frequency: Usually once or twice daily, depending on protocol

Optimal dosage is still under research and should be tailored individually by a medical professional.

Safety and Side Effects

AOD-9604 is generally well tolerated. Reported side effects are mild and usually temporary:

  • • Redness at injection site
  • • Swelling
  • • Itching
  • • Bruising

Unlike HGH, AOD-9604 has not been consistently linked to changes in blood sugar levels, growth abnormalities, or systemic side effects.

Treatment Process at The Catalyst Clinic

1

Consultation

Review of your medical history and health goals.

2

Personalised Plan

If appropriate, AOD-9604 may be included in your peptide therapy programme.

3

Ongoing Monitoring

Regular check-ups ensure safety and track results.

Our clinics in London, New York, and Zurich provide advanced peptide therapies with expert medical support.

 FAQs

  • It is primarily researched for fat reduction, weight management, and potential cartilage protection.

  • It is a fragment of HGH that focuses on fat metabolism only, without growth-promoting effects.

  • Studies suggest it is generally well tolerated, with mild side effects limited to injection site reactions.

  • Yes. The Catalyst Clinic offers consultations and supervised peptide therapy including AOD-9604 at our London clinic.

Book a Consultation

Looking to explore AOD-9604 peptide therapy for weight management?
Contact The Catalyst Clinic in London, New York, or Zürich today to book your consultation.